Analysts Set Insulet Corporation (NASDAQ:PODD) PT at $235.25

Insulet Corporation (NASDAQ:PODD) has earned an average rating of “Moderate Buy” from the twenty-eight research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $235.25.

Several equities analysts have recently issued reports on PODD shares. Leerink Partners reduced their target price on Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Truist Financial dropped their price target on Insulet from $219.00 to $210.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Jefferies Financial Group cut their price objective on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. The Goldman Sachs Group restated a “buy” rating and issued a $205.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. Finally, Benchmark reissued a “buy” rating on shares of Insulet in a report on Wednesday, May 27th.

Insulet Price Performance

Insulet stock opened at $164.06 on Friday. Insulet has a fifty-two week low of $138.79 and a fifty-two week high of $354.88. The stock has a market cap of $11.36 billion, a PE ratio of 38.15, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. The firm’s 50-day simple moving average is $153.00 and its 200 day simple moving average is $206.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same period in the prior year, the firm posted $1.02 EPS. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts predict that Insulet will post 6.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.36% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insulet

Several large investors have recently modified their holdings of the stock. Nordea Investment Management AB lifted its holdings in Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after purchasing an additional 142,922 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Insulet by 26.5% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock worth $12,484,000 after purchasing an additional 9,206 shares in the last quarter. Zevenbergen Capital Investments LLC bought a new stake in shares of Insulet in the fourth quarter valued at approximately $32,143,000. Aberdeen Group plc raised its position in shares of Insulet by 45.6% in the fourth quarter. Aberdeen Group plc now owns 225,429 shares of the medical instruments supplier’s stock valued at $64,076,000 after purchasing an additional 70,607 shares during the period. Finally, Gradient Investments LLC raised its position in shares of Insulet by 17.9% in the fourth quarter. Gradient Investments LLC now owns 69,161 shares of the medical instruments supplier’s stock valued at $19,658,000 after purchasing an additional 10,497 shares during the period.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet provided an update on its ongoing EVOLUTION T1D clinical study, which is testing a next step in automated insulin delivery and could support the long-term growth story for its Omnipod platform. Article link
• Neutral Sentiment: Several firms issued deadline reminders and investor alerts related to the already-filed securities class action, keeping the lawsuit in focus but not adding new allegations. Article link
• Neutral Sentiment: Additional law-firm notices reiterated the August 31 lead-plaintiff deadline, underscoring ongoing legal risk but mainly serving as promotional updates rather than fresh company developments. Article link
• Negative Sentiment: Multiple securities-fraud class action notices highlighted alleged investor harm tied to Insulet’s manufacturing quality and prior device corrections, which is likely weighing on sentiment and shares. Article link

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.